

CHAPTER 1 A JOURNEY BEYOND THE BLUR










































































































































CROSS-UNIVE

REFERENCES:

- Gore, Daniel M., et al. "Accelerated pulsed high-fluence corneal cross-linking for progressive keratoconus." American journal of ophthalmology 221 (2021): 9-16.
- Garcia-Ferrer, Francisco J., et al. "Corneal ectasia preferred practice patterno"."
 Ophthalmology 126.1 (2019): P170-P215.
- 3. Moramarco, Antonio, et al. "Efficacy and safety of accelerated corneal cross-linking for progressive keratoconus: a 5-year follow-up study." Journal of Refractive Surgery 36.11 (2020): 724-730.
- Bui, Anh D., et al. "Keratoconus diagnosis and treatment: recent advances and future directions." Clinical Ophthalmology (2023): 2705-2718.

INDICATIONS:

Intended Use

The KXL® System is intended for illuminating the cornea during corneal cross-linking procedures stabilizing cornea which have been weakened by disease or by refractive surgery.

Safety Information

The KXL® System is contraindicated where the corneal thickness, with epithelium, is less than < 375 microns, in corneal melting disorders, aphakic patients, pseudophakic patients without UV blocking lens implanted, pregnant and nursing women, and children. Possible risks may include corneal haze, delayed epithelial healing, corneal edema, stromal scarring, keratitis by infection and sterile infiltrates. For full information consult the directions for use.

©2025 Glaukos. iLink™ V is a trademark of Glaukos Corp. KXL® and VibeX Rapid™ are trademarks of Avedro, a Glaukos Company. PM-EU-0361

AVEDRO, A GLAUKOS COMPANY

